Novartis Pharmaceuticals Corporation.
The FDA granted approval to Novartis Pharmaceuticals Corporation for Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, to be used in the treatment of certain anaplastic thyroid cancers.
Health and Fitness

FDA Approves New Uses for Two Drugs Used for Treatment of BRAF-positive Anaplastic Thyroid Cancer

by on

More in Health and Fitness:

Novartis Pharmaceuticals Corporation.
The FDA granted approval to Novartis Pharmaceuticals Corporation for Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, to be used in the treatment of certain anaplastic thyroid cancers.
Silver Spring, Maryland—(ENEWSPF)—May 4, 2018
Contact: Sandy Walsh

The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has…

Proud member of LION Publishers

Articles published under the "eNews Park Forest" byline may be press releases or news prepared by official representatives of organizations.

Facebook X Instagram

Most read stories this week

Take a Survey

ARCHIVES